Clinical Trial Evidence for Retatrutide The most widely referenced data comes from a Phase 2 trial published in the New England Journal of Medicine in 2023
Important safety considerations include a boxed warning for thyroid C-cell tumors, contraindication in patients with personal/family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, and precautions regarding pregnancy (not recommended), reduced oral contraceptive effectiveness, and risks of pancreatitis, gallbladder disease, and acute kidney injury
The FDA has updated Ozempics label to warn about gastrointestinal obstruction and gastroparesis, a condition involving delayed stomach emptying
Lifestyle interventions are still far more common than pharmacotherapy, said Brianna Cartwright, Truvetas senior research analyst, noting a reluctance among families to embrace medications
This dual-action mechanism makes tirzepatide a bit of an overachiever